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78th Meeting of Ulster Society of Internal 
Medicine, Friday 19th October 2007. 
Ulster Medical Society Rooms,  
Belfast City Hospital, Belfast.
AGENDA
1.55pm  Welcome -  Chairman:  Dr David Higginson
2.00pm  Plenary I – presented abstracts
3.10pm  Invited Lecture. “Management of Upper GI 
Bleeding’. 
Dr Tony Tham, Ulster Hospital.
3.35pm  Afternoon Tea
4.00pm  Invited case from Belfast City Hospital
4.10pm  Plenary II - presented abstracts. 
4.35pm  Presentation of prize for best abstract
4.40pm  Guest lecture: “Biologic Therapies in Psoriatic 
Arthritis”  
Prof Oliver Fitzgerald  Consultant Rheumatologist, 
St Vincent’s University Hospital Dublin.  
PRESENTED ABSTRACTS 
1.  Prevalence  of  cardiac  channelopathies  in  a  tertiary 
referral centre in Northern Ireland
JR  Bennett,  J  McOsker,  TCL  Jardine,  PJ  Scott,  PP 
McKeown. 
Regional Medical Cardiology Centre, Royal Victoria Hospital, Belfast Health 
and Social Care Trust, Belfast
Several primary cardiac arrhythmia syndromes are known 
to have a genetic basis and are caused by mutations in ion 
channel genes. These mutations cause abnormal ionic currents 
which can lead to ECG abnormalities and cardiac arrhythmias. 
These syndromes, known as cardiac channelopathies, include 
long QT syndrome (LQTS), short QT syndrome (SQTS), 
Brugada syndrome (BS) and catecholaminergic polymorphic 
ventricular tachycardia (CPVT), and are responsible for up to 
40% of all cases of Sudden Adult Death Syndrome1.
To date 32 families have been genetically diagnosed with 
LQTS. In these families 250 individuals have been genetically 
screened; 141 (56%) carry a mutation for LQTS and 95 (38%) 
are non-carriers (results pending in 14 (6%)). A further 10 
families have a clinical diagnosis of LQTS with no gene 
mutation identified (sensitivity of 70% for picking up LQTS2). 
These  families  were  identified  following;  investigation  of 
syncope (35.4%), routine ECG (19.3%), screening following 
sudden death in family (16.1%), successful resuscitation of 
cardiac arrest (13%), investigation of palpitations (13%) and 
investigation following a near drowning episode (3.2%). Nine 
families have been referred for investigation of likely BS; 
3 have mutations in SCN5A detected by genetic screening 
(sensitivity of 30% for picking up BS2). One family has been 
diagnosed with CPVT on genetic screening and CPVT is a 
possible diagnosis in 1 other family. No SQTS families have 
been identified.
Cardiac  channelopathies  are  important  primary  cardiac 
arrhythmia  syndromes.  Genetic  testing  aids  in  the 
identification of individuals carrying these gene mutations so 
that appropriate management can be implemented.
1.   Tan HL, Hofman N, Van LI, Van der Wal AC, Wilde AA. Sudden 
unexplained death: heritability and diagnostic yield of cardiological 
and  genetic  examination  in  surviving  relatives.  Circulation 
2005;112(2):1457-1459
2.   Garratt CJ, Elliott PM, Behr E, Blair E, Connelly D, Cowan C, Davidson 
N, Grace A, Griffith M, Jolly A, Lambiase P, McKenna W. Heart Rhythm 
UK Familial Sudden Death Syndromes Statement Development Group. 
Clinical indications for genetic testing in familial sudden cardiac death 
syndromes: a HRUK position statement. Heart Online 2007;doi:10.1136/
hrt.2007.127761.
2. Anti-Xa activity with local treatment protocols for acute 
coronary syndrome.
KS Lyons, IBA Menown .
Craigavon Cardiac Centre, Craigavon Area Hospital, Craigavon.
Abstract:  Enoxaparin  is  now  the  recommended  anti-
thrombotic  treatment  for  patients  with  acute  coronary 
syndromes (ACS). While plasma monitoring of the biological 
activity  of  enoxaparin  is  not  usually  required  due  to  its 
predictable pharmacokinetics and pharmacodynamics, it may 
be assessed by measuring plasma anti-Xa levels (therapeutic 
range  0.5-1.2IU/ml).  In  patients  with  ACS,  low  anti-Xa 
activity is independently associated with increased 30-day 
mortality.1 Guidelines and licensing suggest an ACS treatment 
dose of 1 mg/kg bd, although in Northern Ireland, many local 
treatment protocols dose cap enoxaparin at 60mg bd to reduce 
bleeding risk. We studied 20 consecutive patients admitted 
with ACS. All received 60mg enoxaparin bd. Peak plasma 
anti-Xa activity was measured as described by Montelescot 
et al, 4-6 hours after administration of enoxaparin. 
Results: Of the 20 patients, 14 were male, mean TIMI risk 
score was 4.2/7 and mean weight was 81.9kg.   One third 
(35%) of patients (5 male, 2 female) were found to have © The Ulster Medical Society, 2008.
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sub-therapeutic  anti-Xa  levels  (mean  0.35  IU/ml,  range 
0.2–0.49 IU/ml). The remainder had anti-Xa levels within 
the therapeutic range (mean 0.73 IU/ml, range 0.5 – 1.12 IU/
ml). Mean weight was higher in those with sub-therapeutic 
compared with therapeutic anti-Xa levels (89.9 vs 77.6kg; 
p value = 0.041). 5 patients in the therapeutic group and 
1 patient in the non-therapeutic group had impaired renal 
function (eGFR 30-60 mls/min). In conclusion, dose capping 
of enoxaparin at 60mg bd in ACS patients may result in a 
significant  proportion  achieving  sub-therapeutic  anti-Xa 
levels, potentially correlating with poorer outcome.
1.   Montalescot G, Collet JP, Tanguy ML, Ankri A, Payot L, Dumaine R, 
Choussat R, Beygui F, Gallois V , Thomas D. Anti-Xa activity relates to 
survival and efficacy in unselected acute coronary syndrome patients 
treated with enoxaparin. Circulation 2004;110:392-398.
3. A randomised placebo-controlled interventional trial of 
omega-3-polyunsaturated fatty acids on endothelial function 
and disease activity in systemic lupus erythematosus
SA Wright1,2,3, FM O’Prey1, MT McHenry2,3, WJ Leahey, 
AB Devine1, EM Duffy2,4, DG Johnston1, MB Finch2,3, GE 
McVeigh1, AL Bell2,3
1  Department  of  Therapeutics  and  Pharmacology,  Queens  University 
Belfast,  2Lupus Research Group, Queens University Belfast, 
3  Department of Rheumatology, Musgrave Park Hospital, Belfast, 
4  Northern Ireland Centre for Food and Health (NICHE), Department of 
Biomedical Sciences, University of Ulster.
We  aimed  to  determine  the  clinical  effect  of  dietary 
supplementation with low dose omega-3-polyunsaturated fatty 
acids on disease activity and endothelial function in patients 
with systemic lupus erythematosus. 
A  24  week  randomised  double-blind  placebo-controlled 
parallel trial of the effect of 3g of omega-3-polyunsaturated 
fatty acids on 60 patients with SLE was performed.   Serial 
measurements of disease activity using the revised Systemic 
Lupus  Activity  Measure  (SLAM-R)  and  British  Isles 
Lupus Assessment Group index of disease activity for SLE 
(BILAG), endothelial function using flow mediated dilation 
of the brachial artery (FMD), oxidative stress using platelet 
8-isoprostanes and analysis of platelet membrane fatty acids 
were taken at baseline, 12 and 24 weeks.
In the fish oil group there was a significant improvement at 
24 weeks in SLAM-R (from 9.4±3.0 to 6.3±2.5, p<0.001); in 
BILAG (from 13.6±6.0 to 6.7±3.8, p<0.001); in FMD (from 
3.0% (-0.5-8.2) to 8.9% (1.3-16.9), p<0.001) and in platelet 
8-isoprostanes (from 177pg/mg protein (23 – 387) to 90 pg/
mg protein (32 – 182), p = 0.007).
Low dose dietary supplementation with omega-3 fish oils 
in SLE not only has a therapeutic effect on disease activity 
but also improves endothelial function and reduces oxidative 
stress and may therefore confer cardiovascular benefits.
4. Effect of ingestion of food on the inhibition of DPPIV 
activity by oral metformin in type 2 diabetes.
J Cuthbertson1, S Patterson2, FPM O`Harte2, PM Bell1
1  Regional  Centre  for  Endocrinology  and  Diabetes,  Royal  Victoria 
Hospital, Belfast. 2School of Biomedical Sciences,University of Ulster, 
Coleraine
The incretin hormones glucagon-like peptide-1 (GLP-1) and 
glucose-dependent insulinotropic polypeptide (GIP) constitute 
the enteroinsular axis which promotes postprandial insulin 
secretion. The  therapeutic  potential  of  these  hormones  in 
diabetes is limited by their rapid inactivation by the enzyme
dipeptidylpeptidase-IV (DPP-IV). Here we investigated the 
acute effects of metformin in the presence and absence of 
food on DPP-IV activity in type 2 diabetes
Ten  subjects  with  type  2  diabetes  (6  male/4  female,  age 
65.8±15.8  years  (mean±SEM),  body  mass  index  30.0± 
7.5kg/m2, HbA1c 6.3±1.2%) received metformin 1g orally 
or placebo together with a standard mixed meal (SMM) in a 
random crossover design. Six subjects reattended fasting and 
received metformin 1g without a SMM.
Following SMM (n=10), DPP IV activity was not suppressed 
by  metformin  compared  with  placebo  (area  under  curve 
AUC  0-4h 1574±4 and 1581±8 µmol/min respectively). No 
differences were observed in plasma glucose, insulin and total 
GLP-1. After fasting (n=6), DPP IV activity was suppressed 
(P<0.02) when compared to those given metformin with a 
SMM (AUC 0-4h 1494±9 vs 1578±4 µmol/min). Metformin 
plasma levels were significantly higher (P<0.03) after fasting 
than SMM (AUC 0-4h 457±55 vs 350±66 mcg/ml).
Thus metformin inhibits DPP IV activity in type 2 diabetic 
patients  in  the  fasting  state  but  not  when  taken  with  a 
standard mixed meal. Metformin  plasma concentrations are 
lower if taken with food. Metformin may have potential for 
combination therapy with incretin hormones.
5. An  interesting  cause  of  hypopituitarism:  infiltrative 
versus idiopathic
AS  Lewis1,  ME  Callender2,E  Chew3,  CH  Courtney1,  N 
McDougal2, AB Atkinson1
1   Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, 
Belfast. 
2   Hepatology Unit, Royal Victoria Hospital, Belfast. 
3   Cardiology Department, Belfast City Hospital, Belfast.
Hypopituitarism usually occurs as the result of a pituitary 
tumour or as a consequence of its treatment.  If, however, 
pituitary imaging is negative then there are a wide variety of 
alternative causes but no firm consensus as to which should be 
actively sought.  We present two cases of apparent idiopathic 
hypopituitarism  in  whom  the  underlying  diagnosis  was 
delayed with potentially serious side effects.
Case Report: A 32 year old male presented with symptoms 
of  hypogonadism.    Testosterone  (<0.7nmol/L;  N  10.5-30 
nmol/L) and gonadotrophins were low (FSH <0.5 U/L; LH 
<0.5 U/L) and prolactin was normal (118mU/L).  Thyroid 
function was normal (fT4 9.7pmol/L; N 7.6-19.7 pmol/L, 
TSH  1.33mU/L;  N  0.45-4.5  mU/L).    Insulin  tolerance 
testing established a normal cortisol peak of 1002nmol/L 
but  suboptimal  growth  hormone  response  (8.1mU/L)  to 
hypoglycaemia.  Pituitary imaging was normal.  He presented 
5 years later in congestive cardiac failure with an elevated 
ferritin (6309 ug/L; N 18-325ug/L) and transferrin saturation 
(100%).  Homozygosity for the C282Y mutation confirmed 
the diagnosis of haemochromatosis.
A 51 year old female presented with non-specific symptoms.   
Initial  testing  suggested  hypopituitarism  with  a  random © The Ulster Medical Society, 2008.
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cortisol of <30nmol/L and a low free T4 (6.9 pmol/L) with 
normal TSH  (2.3  mU/L).    Prolactin  was  1190mU/L  and 
gonadotrophins were post menopausal (FSH 26.6 U/L, LH 
16.8U/L).  Insulin tolerance testing confirmed an inadequate 
cortisol response (<30nmol/L) but a normal GH response 
(41.3  mU/L)  to  hypoglycaemia.    Pituitary  imaging  was 
normal.    Four  years  later,  investigation  revealed  a  raised 
ferritin (389ug/L) and transferrin saturation (74%).  She was 
heterozygous for the C282Y mutation and iron overload was 
confirmed at liver biopsy.
Haemochromatosis  causes  pituitary  dysfunction  by 
depositing iron in the anterior pituitary.  Due to its rarity as 
a cause of hypopituitarism, it is not always considered by 
endocrinologists as a potential diagnosis.  Imaging is usually 
normal and patients are often wrongly labelled as having 
idiopathic  hypopituitarism.    However,  early  diagnosis  is 
important as treatment may reverse the pituitary deficit and 
prevent future sequelae in other organs.  We recommend iron 
studies in all patients who present with hypopituitarism and 
normal pituitary imaging.
6.  Implementing  the  European  Society  Of  Cardiology 
Guidelines for evidence based therapy in Heart failure: 
An audit of Pharmacotherapy at discharge from an Acute 
Hospital.
K Morrice, J Hastings. B McClements.
Cardiology Dept,  Mater Hospital, Belfast
The consistent implementation of guidelines on the use of 
evidence-based drug therapy in heart failure patients remains 
a challenge in clinical practice. The purpose of this study was 
to determine the extent of this problem in a single centre that 
seeks to adhere to European Society of Cardiology guidelines 
(2005), to discern its possible causes and to assess whether 
there is a difference depending on LV systolic function.
281  consecutive  patients  (150  male,  mean  age  77  years) 
admitted  between  April  2005  and  December  2006  were 
identified from the Mater Hospital Heart Failure database.   
Of these, 245 patients who had recent echocardiographic data 
available formed the study population: 154 (63%) had LV 
systolic dysfunction (LVEF < 40%) (Group LV-S) and 91 had 
relatively preserved systolic function (Group LV-P).
Results:  The groups were similar except for percentage with 
hypertension (LV-P 80% v LV-S 44%, p<0.001). Mortality 
was 10.4% in LV-S and 10.9% in LV-P (p NS).  Mean serum 
creatinine was 149µmol/l in LV-S and 135µmol/l in LV-P on 
admission and 158 µmol/l and 141 µmol/l respectively at 
discharge. 
Review of the clinical records of 24 patients in LV-S not on 
treatment with ACEi/ARB at discharge revealed that 20 had 
significantly impaired renal function (mean serum creatinine 
264 µmol/l), 2 had profound hypotension with initiation of 
ACEi, one had severe aortic stenosis and one self-discharged 
against advice.  
The proportion (%) of patients in each group on prognosis 
modifying medication on admission (A) and at discharge 
(D) were:
LV-S LV-P
ACEi/ARB A 60 46
D 83 76
Beta-Blocker A 55 55
D 91 94
AA A 30 24
D 50 49
ACEi  / ARB= Angiotensin  converting  enzyme  inhibitor  or Angiotensin 
Receptor Blocker; 
AA = aldosterone antagonist
Conclusions: In this single centre study, use of beta-blockers 
was very satisfactory. All LV-S patients were on treatment 
with ACEi/ARB  or  had  a  documented  contra-indication, 
usually renal impairment.  There appears to be scope for 
greater use of AA in LV-S. It was also interesting to note the 
frequent use of AA in heart failure with relatively preserved 
systolic function.
7. Trends  In  Lipid  Levels  In  Patients Admitted With 
Myocardial Infarction To A Regional Cardiology Centre 
2000-2006
P  Scott,  V  Kodoth,  R  Noad,  J  Bennet,  C  Murphy,  G 
Manoharan, AAJ Adgey.
Regional  Medical  Cardiology  Centre  (RMCC),  Royal Victoria  Hospital 
Belfast, Belfast Trust, Belfast, UK.
Introduction:  Hypercholesterolemia is a major risk factor 
for coronary artery disease.  Revised Joint British Society 
Guidelines  2005  (JBS-2)  have  recommended  tighter  lipid 
targets  for  both  primary  and  secondary  prevention.    We 
reviewed trends in fasting lipid levels of patients admitted 
with Myocardial Infarction (MI) to our centre and assessed 
compliance with these guidelines. 
Methods: Fasting lipid profiles were analysed on patients 
admitted with an MI from January 2000 to December 2006 
(n=1346).  For patients admitted in 2005 lipid profile values 
were  re-evaluated  at  least  6  months  after  admission  to 
determine if JBS-2 target lipid values had been achieved.  
Results:  Average  Total  Cholesterol  decreased  from  5.26 
mmol/L in 2000 to 4.73 mmol/L in 2006 (p=0.026), LDL 
Cholesterol  from  3.14  mmol/L  in  2000  to  2.57  mmol/L 
in  2006  (p<0.001)  and  HDL  Cholesterol  rose  from  1.11 
mmol/L  in  2000  to  1.58  mmol/L  in  2002  (p=0.013)  but 
declined to 1.33 mmol/L in 2006 (p=0.423).  ST elevation 
Myocardial  Infarction  (STEMI)  patients  had  significantly 
higher Total Cholesterol (5.11 Vs 4.78; p<0.001), LDL (2.97 
Vs 2.69; p<0.001) and lower HDL (1.28 Vs 1.39: p=0.399) 
when compared with those admitted with Non ST-elevation 
Myocardial Infarction (NSTEMI).  In 2005, 69% had achieved 
Total Cholesterol, 74% LDL and 71% HDL cholesterol targets 
6 months after their admission.  
Conclusion:  Our  study  reveals  reduction  in  lipid  profile 
values on admission from 2000 to 2006. We also noted that 
patients admitted with STEMI had a higher Total Cholesterol, 
LDL and lower HDL than NSTEMI. Current guidelines for 
primary and secondary prevention of coronary heart disease 
has led to more fastidious use of anti-lipid medications and 
has had a significant impact on the reduction of cholesterol.